Company: CERO
Filing Date: 2025-06-25
Form Type: 424B3
Source: 0001213900-25-057780
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-06-25
Form: 424B3
Chunk 2
---
 pursuant to Section 12(b) of the Act:

| Title of                                                                             
 each class                                                                           |     | Trading Symbol(s) |     | Name of each exchange 
 on which registered   |
| Common Stock, par value $0.0001 per share                                            |     | CERO              |     | Nasdaq                
 Capital Market        |
| Warrants, each warrant exercisable for one two-thousandth of a share of Common Stock |     | CEROW             |     | Nasdaq Capital Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On June 17, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), issued a press release announcing that the U.S. Food and Drug Administration had granted the Company’s Orphan Drug Designation for the Company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

| Exhibit 
 No.     
 99.1    |     | Description                                                                  
 Press release, dated June 17, 2025.                                          |
|:--------|:----|:-----------------------------------------------------------------------------|
| 104     |     | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

<div align='center'>1

SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Dated: June 17, 2025 | CERO THERAPEUTICS 
 HOLDINGS, INC.    |                         |
|:---------------------|:------------------|:------------------------|
|                      | By:               | /s/                     
 Chris Ehrlich           |
|                      | Name:             | Chris Ehr